Metastasis is a primary cause of death in patients with advanced solid cancers. MDA-9 is a pro-metastatic gene that is associated with multiple stages in the metastatic process, making it a potentially viable target for therapy. This scaffold protein contains two PDZ domains that interact with important cancer-related proteins. IVMT-Rx-3, a novel hybrid small molecule inhibitor, blocks MDA-9 protein-protein interactions by employing a small molecule which interacts with one PDZ domain linked to a peptide which interacts with the second PDZ domain. IVMT-Rx-3 promotes immune cytotoxicity by inducing an immunostimulatory tumor microenvironment and synergizes with immunotherapy.

PTK7 is overexpressed in a wide range of solid tumors and implicated in the Wnt signaling pathway that promotes cancer development and metastasis. Although clinically validated, current PTK-7 targeting ADCs have only shown moderate efficacy in limited tumor types. Kong and colleagues developed MTX-13, a novel topoisomerase I inhibitor exatecan-based ADC with a significantly...

You do not currently have access to this content.